Conference LibraryGated
Panel 3 · '9 patients all developed CAR-T cells in vivo · levels similar to ex vivo'
Panel 3 主讲人讨论 ESO-T01 phase 1 (9 patients · r/r MM) 时的关键 quote。 Speaker attribution 守 Wall 5:transcript 未明示具体名字 · 保留 unknown_panelist_panel3_01。这是 m623 客户洞察 / m624 demo 时 feasibility claim 的 primary anchor。
- Type
- quote
- Domain
- conference
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- panel_quote_with_attribution
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "feasibility quote · 3-4 month follow-up insufficient for late-stage outcome claim"
- quote_text
- "one earlier publication and another more recent one, in total they describe nine patients · all nine developed CAR-T cells · levels similar to ex vivo · vector infusion toxicity · CRS days later · extramedullary lesions eliminated · 3-4 month follow-up"
- panel
- panel_3
- topic
- in_vivo_car_t_feasibility
- significance
- Strong anchor quote for feasibility framing · 9/9 CAR-T 生成成功 · levels similar to ex vivo · extramedullary lesion elimination。 m623 在 SunVax pilot proposal / Demo 时可引用作为 in vivo CAR-T feasibility 的 pan
- speaker_name
- unknown_panelist_panel3_01
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.